China Medical System and Incyte partner on dermatology drug
- ByInvesting.com
- •
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. Its products include VALTOCO, a diazepam nasal spray to treat seizure clusters; Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu to treat acute heart failure; Deanxit for mild-to-moderate depression, anxiety, and psychosomatic affections; METOJECT, a methotrexate injection for recalcitrant disabling psoriasis; and Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis. The company also offers Salofalk for treating Ulcerative Colitis and Crohn’s disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; ILUMETRI, a tildrakizumab injection to treat moderate-tosevere plaque psoriasis; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar. In addition, it provides Aethoxysklerol for sclerotherapy of different varicose veins; Heling Soothing product for skin soothing; Vmonalisa for mid to deep dermal implantation; Neauvia Hyaluronic Acid series; EyeOP1 to treat glaucoma; Ganfule capsules for the treatment of primary cancer of the liver; Imdur for the treatment of coronary heart disease, chronic heart failure, and myocardial infarction, as well as for prevention of vasospasm and mixed angina; MOVICOL for treating chronic constipation and faecal impaction; and MeteoSpasmyl to treat gastrointestinal flatulence and pain. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.